SCHEMBL1638855

SCHEMBL1638855

Cc1ccc(/C(=N/c2c(C(C)C)cccc2C(C)C)c2cccc(Br)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSL P07711 6/20 0.51
CTSB P07858 2/20 0.51
SCN5A Q14524 1/20 0.39
SCN2A Q99250 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
ESR2 Q92731 2/20 0.36
ESR1 P03372 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12647006 1.00 CTSL (0.51) CTSLCTSBSCN5ASCN2ASMN1; SMN2
SCHEMBL1638856 1.00 CTSL (0.51) CTSLCTSBSCN5ASCN2ASMN1; SMN2
SCHEMBL12646934 0.90 SMN1; SMN2 (0.43) CTSLCTSBSMN1; SMN2NPC1RAB9A
SCHEMBL1638849 0.90 SMN1; SMN2 (0.43) CTSLCTSBSMN1; SMN2NPC1RAB9A
SCHEMBL1638850 0.90 SMN1; SMN2 (0.43) CTSLCTSBSMN1; SMN2NPC1RAB9A
SCHEMBL12765349 0.89 CTSL (0.45) CTSLCTSBSCN5ASCN2ASMN1; SMN2
SCHEMBL12765490 0.80 SMN1; SMN2 (0.37) CTSLCTSBSMN1; SMN2NPC1RAB9A
SCHEMBL12726482 0.79 NPC1 (0.48) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL1638479 0.79 NPC1 (0.48) SMN1; SMN2NPC1RAB9ACASP3SENP8
SCHEMBL1638478 0.79 NPC1 (0.48) SMN1; SMN2NPC1RAB9ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493932-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056423-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098429-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 CTSL 3353/4885CTSB 3002/4885SCN5A 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.